Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)

NCT ID: NCT00874120

Last Updated: 2015-03-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 116 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-12-31
• Study Completion Date: 2009-02-28

Brief Summary

Randomized, placebo-controlled double-blind, crossover design study; 116 subjects randomized on Day 1 to obtain 98 completed subjects. Study will be composed of a 7-day period of therapy with randomized active or placebo treatment with a subsequent 6-8 day washout period, followed by a second 7-day period of double-blind therapy with the other agent. Ambulatory blood pressure measurement will be performed beginning on Day 7 of each treatment period following administration of the study drug.

Conditions

Blood Pressure; Human Experimentation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: DOUBLE

Study Groups

Phenylephrine HCl Extended-Release tablets 30 mg

Phenylephrine HCl Extended Release tablets 30 mg

Group Type: EXPERIMENTAL

Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg

Intervention Type: DRUG

Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.

Placebo

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo taken twice daily (12 hours apart) for 7 days.

Interventions

Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg

Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.

Intervention Type: DRUG

Placebo

Placebo taken twice daily (12 hours apart) for 7 days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy, male or female volunteers must be 18 years or older, with a Body Mass Index (BMI) between 19-30 inclusive [BMI = weight (kilograms)/height (meters squared)].
• Clinical laboratory tests (complete blood count, blood chemistries, urinalysis), Human Immunodeficiency Virus (HIV) antibodies, hepatitis B surface antigen, hepatitis C antibody must be within normal limits or clinically acceptable to the Investigator/Sponsor.
• Drug screen for drugs and alcohol with a high potential for abuse must be negative at screening.
• Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations, procedures or participation.
• Subjects must agree not to take a monoamine oxidase inhibitor (MAOI) for two weeks (14 days) prior to study participation and for two weeks (14 days) after the end of their study participation.
• Subjects must have normal or clinically acceptable physical exam and Electrocardiogram (ECG) intervals (PR, QRS, QT and QTc) on 12-lead ECG (recorded at 25 millimeters/second [mm/s]).
• Subjects must have a mean after 5 minute of rest sitting systolic/diastolic office blood pressure ≤ 138/88 millimeters of mercury (mmHg).
• Subjects with controlled diabetes prior to entry must have a mean sitting after 5 minute of rest systolic/diastolic office blood pressure ≤ 128/78 mmHg from non-dominated arm
• Females must have the urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1 of Period 1.
• Female subjects of childbearing potential must be using medically acceptable birth control measures.
• Subjects must understand the dosing schedule.
• Subjects must be able to read and write in English.

Exclusion Criteria

• Subjects must not have any significant medical condition which, in the judgment of the Investigator, is a contraindication to the use of phenylephrine HCl, might interfere with the study or requires treatment expected to affect the blood pressure. These may include hyperthyroidism, hypothyroidism, uncontrolled diabetes mellitus, coronary heart disease, ischemic heart disease, elevated intraocular pressure, prostatic hypertrophy.
• Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration.
• Subjects who have received an investigational drug within 30 days prior to study dosing.
• Subjects who are, appear to be, or are known, current or former drug addicts or alcoholics.
• Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody.
• Subjects who are positive for HIV antibodies.
• Subjects who have a clinically significant history of food or drug allergy.
• Subjects who have a known allergy or intolerance to phenylephrine HCl.
• Females who are pregnant, nursing or unwilling to use/practice adequate contraception (hormonal, Intrauterine Device, barrier method, etc.).
• Subjects taking topical or oral decongestant products within 7 days of Visit 2.
• Subjects taking antihypertensive medication.
• Subjects taking monoamine oxidase inhibitors.
• Subjects taking tricyclic antidepressants (e.g. amitriptyline, nortriptyline, imipramine)
• Subjects taking antithyroid medication (e.g. propylthiouracil, methimazole, iodides).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bayer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

CL2007-07

Identifier Type: -

Identifier Source: secondary_id

P07529

Identifier Type: OTHER

Identifier Source: secondary_id

18121

Identifier Type: -

Identifier Source: org_study_id